Interactive Session:
80. Can New Antibiotics Save the Day?
Thursday, October 8, 2015: 2:00 PM-3:30 PM
Room: 20--ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the potential role of new antimicrobials in difficult to treat infections due to drug-resistant pathogens
  • identify the limitations of current knowledge with new antimicrobials to predict efficiency in difficult to treat infections
  • utilize new antibiotics for difficult to treat  infections in the absence of randomized clinical trials or robust clinical data

Target Audience: Pharmacists, Members-in-training, Infectious diseases physicians, Infectious diseases pediatricians, Healthcare workers, Fellows, Clinicians

Tracks: Trainee, Pediatric ID, Investigative ID, Adult ID

Interactive Moderators:  Cesar Arias, MD, PhD, FIDSA, University of Texas Medical School at Houston and Joshua Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine

Interactive Panelists:  Barbara Murray, MD, FIDSA, University of Texas Medical School , Michael W. Scheld, MD, FIDSA, University of Virginia School of Medicine and Keith Rodvold, Pharm D, FIDSA, University of Illinois at Chicago

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-159-L01-P

Disclosures:

C. Arias, Pfizer: Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Merck Sharp and Dohme: Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
Cubist: Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
Theravance: Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
Bayer: Consultant , Consulting fee
Actavis: Board Member and Speaker's Bureau , Speaker honorarium
Novartis: Consultant and Speaker's Bureau , Consulting fee and Speaker honorarium

J. Nosanchuk, None

B. Murray, Cubist/Merck: Grant Co-Investigator , Grant recipient
Theravance: Grant Co-investigator , Grant recipient
Actavis/Forest: Grant Co-investigator , Grant recipient

M. W. Scheld, None

K. Rodvold, The Medicine Company: Consultant , Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
Theravance Biopharma: Grant Investigator , Investigator and Scientific Advisor , Consulting fee and Research grant
Cubist: Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
Tetraphase: Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
Roche: Consultant , Consulting fee
Forrest laboratories: Consultant , Grant Investigator , Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.